Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 2
1991 2
1993 2
1994 1
1995 1
1998 2
1999 3
2000 2
2002 1
2003 8
2004 5
2005 5
2006 4
2007 4
2008 2
2009 6
2010 3
2011 8
2012 2
2013 4
2014 8
2015 10
2016 8
2017 4
2018 8
2019 3
2020 5
2021 7
2022 8
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Gökbuget N, et al. Among authors: reichle a. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Blood. 2018. PMID: 29358182 Free PMC article. Clinical Trial.
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, Faul C, Brüggemann M, Taylor K, Mergen N, Reichle A, Horst HA, Havelange V, Topp MS, Bargou RC. Gökbuget N, et al. Among authors: reichle a. Leuk Lymphoma. 2020 Nov;61(11):2665-2673. doi: 10.1080/10428194.2020.1780583. Epub 2020 Jul 3. Leuk Lymphoma. 2020. PMID: 32619115
Drug Repurposing by Tumor Tissue Editing.
Lüke F, Harrer DC, Pantziarka P, Pukrop T, Ghibelli L, Gerner C, Reichle A, Heudobler D. Lüke F, et al. Among authors: reichle a. Front Oncol. 2022 Jun 24;12:900985. doi: 10.3389/fonc.2022.900985. eCollection 2022. Front Oncol. 2022. PMID: 35814409 Free PMC article. Review.
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.
Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Klobuch S, Thomas S, Pukrop T, Hackl C, Herr W, Ghibelli L, Gerner C, Reichle A. Heudobler D, et al. Among authors: reichle a. Front Pharmacol. 2018 Nov 28;9:1357. doi: 10.3389/fphar.2018.01357. eCollection 2018. Front Pharmacol. 2018. PMID: 30546308 Free PMC article. Review.
A Proteomic Platform Enables to Test for AML Normalization In Vitro.
Meier-Menches SM, Neuditschko B, Janker L, Gerner MC, Schmetterer KG, Reichle A, Gerner C. Meier-Menches SM, et al. Among authors: reichle a. Front Chem. 2022 Feb 1;10:826346. doi: 10.3389/fchem.2022.826346. eCollection 2022. Front Chem. 2022. PMID: 35178376 Free PMC article.
A Computational Model of Tumor Growth and Anakoinosis.
Pantziarka P, Ghibelli L, Reichle A. Pantziarka P, et al. Among authors: reichle a. Front Pharmacol. 2019 Mar 26;10:287. doi: 10.3389/fphar.2019.00287. eCollection 2019. Front Pharmacol. 2019. PMID: 30971926 Free PMC article.
125 results